Immunoglobulin (IgG) Replacement Therapy Industry - Regional Synopsis
North American Market Forecast
North America industry is expected to hold largest revenue share of 36% by 2037. The market is expanding in the region due to the well-developed healthcare infrastructure and a notable prevalence of diseases requiring immunoglobulin therapies. The established healthcare framework enables the delivery of immunoglobulin therapies, contributing to the region’s robust market position. Also, the presence of major key players in the region is propelling the growth of the market in the region. For instance, Pfizer Inc. announced the supplemental biologics license application (sBLA) for PANZYGA® (Immune Globulin Intravenous [Human] – is 10% Liquid Preparation) has been approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients suffering from chronic inflammatory demyelinating polyneuropathy (CIDP). Therefore, these factors are propelling the growth of the market in the region.
European Market Statistics
Immunoglobulin (IgG) Replacement Therapy Market in Europe is poised to hold the second-largest share of 27% by the end of 2037. Rising incidence of several immune-deficiency diseases and rising physician propensity toward immune-deficiency treatments. Additionally, the market is expanding more quickly because of the region's rising congenital AIDS prevalence. As per a report, of the 53 countries in Europe, 49 reported 110,486 HIV cases in 2022. During this time, the number of deaths among those with an AIDS diagnosis fell, reaching 767 deaths in 2022. Furthermore, immunoglobulin products are now safer and easier for patients to obtain thanks to improvements in production and purifying processes. Since more people can now access the required therapy, this has helped the market expand.
